Adverse-event profile of Crataegus spp.: A systematic review

Drug Safety

Volumn 29, Issue 6, 2006, Pages 523-535

  Daniele, Claudia ^a   Mazzanti, Gabriela ^a   Pittler, Max H ^b   Ernst, Edzard ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; ANTITUSSIVE AGENT; BELLADONNA ALKALOID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARDIAC GLYCOSIDE; CARDIOVASCULAR AGENT; CRATAEGISAN; CRATAEGUS EXTRACT; DIGITOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FRANGULA EXTRACT; GLYCOSIDE; NITRATE; OPIPRAMOL; ORAL CONTRACEPTIVE AGENT; PASSIFLORA INCARNATA EXTRACT; ROB 10; TRIAMTERENE; VALERIAN; VASODILATOR AGENT;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; AGEUSIA; AGITATION; ANXIETY; ARTHRITIS; ASTHMA; BACKACHE; BRADYCARDIA; BRAIN DAMAGE; BRONCHITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CRATAEGUS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ECZEMA; EMOTIONALITY; EPISTAXIS; ERYTHEMA; FACE PAIN; FALLING; FLATULENCE; FLU LIKE SYNDROME; FLUSHING; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAND TREMOR; HEADACHE; HEART DISEASE; HEART FIBRILLATION; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYDROCEPHALUS; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; INCREASED APPETITE; INSOMNIA; ISCHEMIA; MENINGOMYELOCELE; MENSTRUATION DISORDER; META ANALYSIS; MIGRAINE; MUSCLE STIFFNESS; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT DISEASE; RESTLESSNESS; REVIEW; RIGOR; SIDE EFFECT; SINUS ARREST; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; TREMOR; VERTIGO; VISUAL DISORDER; VOMITING; WEAKNESS; XEROSTOMIA;

CRATAEGUS; HEART FAILURE, CONGESTIVE; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33744960495     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629060-00005     Document Type: Review

References (41)

1. Chang Q, Zuo Z, Harrison F, et al. Hawthorn. J Clin Pharmacol 2002; 42: 605-12
2. Cupp MJ. Hawthorn. In: Cupp MJ, Annonn J. Toxicology and clinical pharmacology of herbal products. Totowa (NJ): Humana Press, 2000: 253-8
3. Williamson EM. British herbal pharmacopoeia, 1983. Bournemouth: British Herbal Medicine Association (BHMA) Publications, 2003
4. Weiss RF, Fintelmann V. Herbal medicine. New York: Thieme Stuttgart, 2000
5. Newall A, Anderson LA, Phillipson JD. Herbal medicines: a guide for health-care professionals. London: The Pharmaceutical Press, 1996
6. Blumenthal M. The ABC clinical guide to herbs. Austin (TX): American Botanical Council, 2003
7. Blumenthal M, Busse WR, Goldberg A. The complete Commission E monographs. Austin (TX): American Botanical Council, 2000
8. Schussler M, Holz J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneimittel Forschung 1995; 45: 842-5
9. Weiss RF, Fintelmann V. Herbal medicine. New York: Thieme Stuttgart, 2000
10. Rigelsky JM, Sweet BV. Hawthorn: pharmacology and therapeutic uses. Am J Health Syst Pharm 2002; 59: 417-22
11. Società Italiana di Fitoterapia, Organizzazione Mondiale della Sanità (OMS). Monografie di piante medicinali. Vol. 2. Abbiategrasso (Milan), Italy: Le Nuove Scritture, 2004
12. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003; 114: 665-74
13. Reynolds JEJ, editor. Hawthorne. Martindale: the extra pharmacopoeia. London: The Royal Pharmaceutical Society of Great Britain, Pharmaceutical Press, 1996: 1600
14. Iwamoto M, Ishizaki T, Sato T. Klinische Wirkung von Crataegutt® bei Herzerkrankungen ischämischer und/oder hypertensiver Genese: Eine multizentrische Doppelblindstudie. Planta Med 1981; 42: 1-16
15. O'Connolly M, Bernhôft G, Bartsch G. Behandlung âlterer, multimorbider Patienten mit stenokardischen Beschwerden: Eine placebokontrollierte crossover-Doppelblindstudie mit Crataegutt® novo. Therapiewoche 1987; 37: 3587-600
16. O'Connolly M, Jansen W, Bernhôft G, et al. Treatment of decreasing cardiac performance (NYHA stages I to II) in advanced age with standardized crataegus extract. Fortschr Med 1986; 42: 805-8
17. Hanak T, Brûckel MH. Behandlung von leichten stabilen Formen der Angina pectoris mit Crataegutt novo. Therapiewoche 1983; 33: 4331-3
18. Weikl A, Assmus KD, Neukum-Schmidt A. Objective confirmation of the efficacy of a special crataegus extract WS1442 in patients with cardiac insufficiency (NYHA II). Fortschr Med 1996; 114: 291-6
19. Eichstâdt H, Stôrk T, Môckel M. Wirksamkeit und Vertrâglichkeit von Crataegus-Extrakt WS®1442 bei herzinsuffizienten Patienten mit eingeschrânkter linksventrikulârer Funktion. Perfusion 2001; 14: 212-7
20. Leuchtgens H. The crataegus special extract WS 1442 in patients with cardiac insufficiency NYHA II: a placebo-controlled double-blind study. Fortschr Med 1993; 111: 352-4
21. Zapfe G. Clinical efficacy of crataegus extract WS®1442 in congestive heart failure NYHA class II. Phytomedicine 2001; 8: 262-6
22. Tauchert M. Efficacy and safety of crataegus extract WS®1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002; 143: 910-5
23. Staiger J, Kuhn H, Spâth J. Zur kardialen Wirksamkeit von low-dose digitoxin (0.07 mg) and crataegus. Med Welt 1987; 38: 1023-8
24. Eichstâdt H, Bâder M, Danne O. Crataegus-Extrakt hilft dem Patienten mit NYHA II-Herzinsuffizienz. Therapiewoche 1989; 39: 3288-96
25. Weikl A, Noh HS. Der Einfluss von Crataegus bei globaler Herzinsuffizienz. Herz Gefâsse 1992; 12: 516-24
26. Tauchert M, Gildor A, Lipinski J. High-dose crataegus (hawthorn) extract WS®1442 in the treatment of NYHA stage II heart failure. Herz 1999; 24: 465-74
27. Habs M. Prospective, comparative cohort studies and their contribution to the benefit assessment of therapeutic options: heart failure treatment with and without hawthorn special extract WS 1442. Forsch Komplementârmed Klass Naturheilkd 2004; 11: S36-9
28. Alexander A. Klinische Wirkung des Crataegus Extraktes LI132 bei der Therapie der Herzinsuffizienz im Stadium II der New York Heart Association. Eine randomisierte, plazebokontrollierte Doppelblindstudie an N = 73 Patienten [doctoral thesis; online]. Available from URL: http://edoc.hu-berlin.de/ docviews/abstract.php?lang=ger&id=10095 [Accessed 2006 Jan 27]
29. Bôdigheimer K, Chasa D. Effectiveness of hawthorn extract at a dosage of 3 x 100mg per day: multicentre double-blind trial with 85 NYHA stage II heart failure patients. Mûnch Med Wochenschr 1994; 136: S7-S11
30. Schmidt U, Kuhn U, Ploch M, et al. Efficacy of hawthorn (crataegus) preparation LI132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. Phytomedicine 1994; 1: 17-24
31. Tauchert M, Ploch M, Hûbner WD. Effectiveness of the hawthorn extract LI 132 compared with the ACE inhibitor captopril. Mûnch Med Wochenschr 1994; 136: S27-33
32. Fischer K, Jung F, Koscielny J, et al. Crataegus-extract vs methyldidoxin. Mûnch Med Wochenschr 1994; 136: S35-8
33. Fôrster A, Fôrster K, Bûhring M, et al. Crataegus bei mâßiger reduzierter linksventrikulârer Auswurffraktion. Mûnch Med Wochenschr 1994; 136: S21-6
34. Schmidt U, Albrecht M, Podzuweit H. High dosed therapy with crataegus extract in patients suffering from heart failure NYHA stage I and II. Z Phytother 1998; 19: 22-30
35. Rietbrock N, Hamel M, Hempel B. Efficacy of a standardized extract of fresh crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure (NYHA II). Arzneimittel Forschung 2001; 51: 793-8
36. Degenring FH, Suter A, Weber M, et al. A randomised double blind placebo controlled clinical trial of a standardised extract of fresh crataegus berries (Crataegisan®) in the treatment of patients with congestive heart failure NYHA II. Phytomedicine 2003; 10: 363-9
37. Walker AF, Marakis G, Morris AP, et al. Promising hypotensive effect of hawthorn extract: a randomised double-blind pilot study of mild, essential hypertension. Phytother Res 2002; 16: 48-54
38. Barnes J, Mills SY, Abbot NC. Different standards of reporting of ADRs to herbal remedies and conventional OTC medicines: face to face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496-500
39. Ernst E, Pittler MH, Stevinson C, et al. The desktop guide to complementary and alternative medicine: an evidence based approach. Edinburgh: Mosby, 2001
40. Tankanow R, Tamer HR, Streetman DS, et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). Clin Pharmacol 2003; 43: 637-42
41. Mills S, Bone K. The essential guide to herbal safety. Edinburgh: Elsevier Churchill Livingstone, 2005